Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome
- 1 February 1999
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (2) , 600
- https://doi.org/10.1200/jco.1999.17.2.600
Abstract
PURPOSE: Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily. A microencapsulated...Keywords
This publication has 16 references indexed in Scilit:
- An analysis of 8305 cases of carcinoid tumorsCancer, 2000
- Carcinoid tumoursPostgraduate Medical Journal, 1997
- Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patientsMetabolism, 1996
- Carcinoid Tumors: Development of Our KnowledgeWorld Journal of Surgery, 1996
- The epidemiology of carcinoid tumours in England and ScotlandBritish Journal of Cancer, 1994
- Metastatic Carcinoid Tumors and the Malignant Carcinoid SyndromeAnnals of the New York Academy of Sciences, 1994
- Effects of Sandostatin on Neuroendocrine Tumours of the Gastrointestinal SystemPublished by Springer Nature ,1993
- Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the GutAnnals of Internal Medicine, 1989
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986
- Carcinoid TumorsAn analysis of 2837 casesCancer, 1975